Journals / Selçuk Tıp Dergisi / 2019 / Cilt: 35 - Sayı: 2

Treatment of Cutaneous Mucormycosis in Patients with Corticosteroid Treatment After Trauma

Travma Sonrasında Kortikosteroid Tedavisi Gören Hastalarda Gelişen Kutanöz Mukormikoz Olgularında Tedavi

Pages
113–119
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Rapid, repetitive and aggressive debridemants should be performed and reconstruction should be planned after cure of the fungi.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Mucormycosis is an infrequent opportunistic fungal infection which may cause an aggressive and invasive soft tissue necrosis.
📊
Key Findings & Data:Patients and Methods: The patients who were admitted to Manisa Celal Bayar University Hospital after multitrauma and given short term corticosteroids due to cranial and spinal injuries and became immuncompromised and diagnosed as facial cutaneous mucormycosis between 2016 and 2018 were included in the study.
💡
Conclusion & Impact:Rapid, repetitive and aggressive debridemants should be performed and reconstruction should be planned after cure of the fungi.
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Mucormycosis is an infrequent opportunistic fungal infection which may cause an aggressive and invasive soft tissue necrosis. It is usually developed in patients with immune system deficiency, and rarely seen in immunocompetant patients. We report prognosis and treatment of the immunocompetan patients that developed facial cutaneous mucormycosis after short term corticosteroid therapy. Patients and Methods: The patients who were admitted to Manisa Celal Bayar University Hospital after multitrauma and given short term corticosteroids due to cranial and spinal injuries and became immuncompromised and diagnosed as facial cutaneous mucormycosis between 2016 and 2018 were included in the study. Prognosis, medical and surgical treatment outcomes of therapy is reported. Results: One patient with malar and maxillary involvement was treated with medical therapy and serial debridements and infection was cured. Reconstruction with free flaps were done, acceptable functional and aesthetic results were achieved. Two patients had adequate therapy and reconstructed with local flaps. One patient was not operated due to recurrent fungal osteomyelitis and intracranial inflammatory findings, and regression in MRI was seen. Conclusion: Mucormycosis should be kept in mind in contaminated wound infections in patients who have been treated with corticosteroids even for a short time after multitrauma. Rapid, repetitive and aggressive debridemants should be performed and reconstruction should be planned after cure of the fungi.

Özet

Amaç: Mukormikozis, invaziv yumuşak doku nekrozu yapabilen ve agresif seyirli nadir bir fırsatçı mantar enfeksiyonudur. Genellikle immun sistem yetersizliği olan hastalarda görülürken, nadiren immunkompetan hastalarda da karşılaşılabilir. Bu yazıda, travma sonrası kısa sureli kortikosteroid tedavisi alan ve ardından fasiyal kutanöz mukormikoz gelişen 4 immunkompetan olgunun prognoz ve tedavisi bildirilmektedir. Hastalar ve Yöntem: Çalışmaya 2016 – 2018 yılları arasında Manisa Celal Bayar Üniversitesi Hastanesi’ne travma sonrasında başvuran, intrakranial veya spinal patolojileri nedeniyle kısa sureli kortikosteroid tedavisi alarak immun sistemi baskılanmış olan ve fasiyal kutanöz mukormikoz tanısı alan dört adet hasta dahil edildi. Prognoz, medikal ve cerrahi tedavi sonuçları değerlendirildi. Bulgular: Malar ve maksiller bölge tutulumu olan bir hastada seri debridmanlar ve medikal tedavilerle kür sağlandı. Serbest fleplerle rekonstruksiyon yapılan hastada estetik ve fonksiyonel olarak kabul edilebilir sonuçlara ulaşıldı. 2 hastanın tedavisi tamamlandıktan sonra lokal fleplerle onarımı yapıldı. Bir hastaya, fungal osteomiyelit ve intrakraniyal inflamatuar değişiklikleri bulunması nedeniyle onarım operasyonu yapılamadı. Bu hastanın takiplerinde MR görüntülemelerinde regresyon saptandı. Sonuç: Multitravma sonrasında, kontamine yara enfeksiyonu meydana gelen ve kısa dönem için bile olsa kortikosteroid tedavisi alan hastalarda mukormikozisin akılda tutulması gerekmektedir. Seri, tekrarlayan ve agresif debridmanlar yapılmalı, rekonstruksiyon planı enfeksiyonda kür sağlandıktan sonra yapılmalıdır.

🔖

Cite This Article

EVRENOS, M. K., ÜNSAL, M. Ö. (2022). Treatment of Cutaneous Mucormycosis in Patients with Corticosteroid Treatment After Trauma. Selçuk Tıp Dergisi, Cilt: 35 - Sayı: 2, 113–119. https://ajindex.com/articles/591827

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Kyriopoulos EJ, Kyriakopoulos A, Karonidis A, et al. Burn injuries and soft tissue traumas complicated by mucormycosis infection: A report of six cases and review of the literature. Ann Burns Fire Disasters 2015;28(4):280-7
  2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: A Review of 929 Reported Cases. Clin Infect Dis 2005;41(5):634-53
  3. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: A review of the clinical manifestation, diagnosis and treatment. Clin Microbiol Infect 2004;10 Suppl.:31-47
  4. Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012;54(SUPPL. 1):23-34
  5. Ferguson A. Rhinocerebral mucormycosis acquired after a short course of prednisone therapy. JAOA J Am Osteopath Assoc 2007;107(11):491-3
  6. Losee JE, Selber J, Vega S, et al. Primary cutaneous mucormycosis: Guide to surgical management. Ann Plast Surg 2002;49(4):385–90
  7. Benedict K, Park BJ. Invasive fungal infections after natural disasters. Emerg Infect Dis 2014;20(3):349-55
  8. Alloway J, Buchsbaum R, Filipov P, et al. Mucormycosis in a patient with sarcoidosis. Sarcoidosis 1995;12(2):143-6
  9. Spellberg B, John Edwards J, Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18(3):556-69
  10. Platauf A. Mycosis mucorina. Virchows Arch. 1885;102:543- 64
  11. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000;13(2):236-301
  12. Moran SL, Strickland J, Shin AY. Upper-extremity mucormycosis infections in immunocompetent patients. Hand Surg 2006;31(7):1201-5
  13. Mizutari K, Nishimoto K, Ono T. Cutaneous mucormycosis. J Dermatol 1999;26:174-7
  14. Koldas K, Solgun G, Deveci A, et al. A Case of cutaneous mucormycosis developing after a traffic accident. Klimik Dergisi/Klimik J 2015;27(1):33-5
  15. Petrikkos G, Skiada A, Sambatakou H, et al. Mucormycosis: Ten-year experience at a tertiary-care center in greece. Eur J Clin Microbiol Infect Dis 2003;22(12):753-6
  16. Kontogiorgi M, Floros I, Koroneos A, et al. Fatal post-traumatic zygomycosis in an immunocompetent young patient. J Med Microbiol 2007;56(9):1243-5
  17. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984;74(1):150-60
  18. Baddley JW, Stroud TP, Salzman D, et al. Invasive mold infections i